FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551928250> ?p ?o ?g. }

• W1551928250 endingPage "6" @default.
• W1551928250 startingPage "3301" @default.
• W1551928250 abstract "1843U89 is a potent inhibitor (Ki = 0.09 nM) of thymidylate synthase (TS; EC 2.1.1.45) that is in clinical trial for the treatment of solid tumors. Although it is an excellent substrate for the folate anabolizing enzyme folylpolyglutamate synthetase (FPGS), 1843U89 differs from other folate-based inhibitors of TS (e.g., CBC3717, D1694, and LY231514), in that the parent compound is as potent an enzyme inhibitor as its polyglutamated analogues. As reported (D.S. Duch et at., Cancer Res., 53:810-818, 1993), 1843U89 is 10-80-fold more cytotoxic than the close structural analogue 1031U89, which is an equipotent inhibitor of TS but is a less efficient substrate for FPGS. This correlation between substrate efficiency for FPGS and cytotoxicity suggests that polyglutamation of 1843U89 contributes to its cytotoxicity. In the current study, we measured intracellular levels of polyglutamated anabolites of 1031U89, 1843U89, and three other benzoquinazoline inhibitors of TS as well as anabolites of D1694 in HCT-8 ileocecal carcinoma cells. Each TS inhibitor was anabolized to polyglutamated analogues with one to five added glutamyl residues after exposure for 24 h to IC90 concentrations (those that inhibit growth by 90% after 72 h of constant exposure). D1694, which requires polyglutamation for potent enzyme inhibition as well as for cytotoxicity, was anabolized mostly to penta- and hexaglutamates, whereas approximately 80% of intracellular 1843U89 was the diglutamate analogue. The substrate efficiency of the benzoquinazolines for FPGS was predictive of the extent of intracellular anabolism. The diglutamate analogue of 1843U89 was only 1/100 as efficient a substrate for further glutamation as was 1843U89 itself. The efficient anabolism to the diglutamate analogue and the lack of dependence on further polyglutamation for enzyme inhibition or cytotoxicity provide a rationale for the reported 1843U89 sensitivity of cells with impaired FPGS activity. As part of an investigation of the effects of polyglutamation, we measured the retention of intracellular 1843U89 and D1694 anabolites after 24 h of exposure to 20 nM of each compound. After 48 h in drug-free medium, 7% of intracellular 1843U89 (mostly diglutamate analogue) and 36% of D1694 (mostly penta- and hexaglutamates) remained in the cells. Because prolonged retention (associated with tissue storage of polyglutamates) can contribute to clinical toxicities, 1843U89 may present fewer long-term toxicities than D1694." @default.
• W1551928250 created "2016-06-24" @default.
• W1551928250 creator A5029107850 @default.
• W1551928250 creator A5074589892 @default.
• W1551928250 date "1996-07-15" @default.
• W1551928250 modified "2023-09-23" @default.
• W1551928250 title "In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase." @default.
• W1551928250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8764125" @default.
• W1551928250 hasPublicationYear "1996" @default.
• W1551928250 type Work @default.
• W1551928250 sameAs 1551928250 @default.
• W1551928250 citedByCount "7" @default.
• W1551928250 crossrefType "journal-article" @default.
• W1551928250 hasAuthorship W1551928250A5029107850 @default.
• W1551928250 hasAuthorship W1551928250A5074589892 @default.
• W1551928250 hasConcept C1008401 @default.
• W1551928250 hasConcept C109316439 @default.
• W1551928250 hasConcept C121608353 @default.
• W1551928250 hasConcept C123321153 @default.
• W1551928250 hasConcept C181199279 @default.
• W1551928250 hasConcept C185592680 @default.
• W1551928250 hasConcept C202751555 @default.
• W1551928250 hasConcept C2776980637 @default.
• W1551928250 hasConcept C2780456651 @default.
• W1551928250 hasConcept C54355233 @default.
• W1551928250 hasConcept C55493867 @default.
• W1551928250 hasConcept C79879829 @default.
• W1551928250 hasConcept C86803240 @default.
• W1551928250 hasConcept C98274493 @default.
• W1551928250 hasConceptScore W1551928250C1008401 @default.
• W1551928250 hasConceptScore W1551928250C109316439 @default.
• W1551928250 hasConceptScore W1551928250C121608353 @default.
• W1551928250 hasConceptScore W1551928250C123321153 @default.
• W1551928250 hasConceptScore W1551928250C181199279 @default.
• W1551928250 hasConceptScore W1551928250C185592680 @default.
• W1551928250 hasConceptScore W1551928250C202751555 @default.
• W1551928250 hasConceptScore W1551928250C2776980637 @default.
• W1551928250 hasConceptScore W1551928250C2780456651 @default.
• W1551928250 hasConceptScore W1551928250C54355233 @default.
• W1551928250 hasConceptScore W1551928250C55493867 @default.
• W1551928250 hasConceptScore W1551928250C79879829 @default.
• W1551928250 hasConceptScore W1551928250C86803240 @default.
• W1551928250 hasConceptScore W1551928250C98274493 @default.
• W1551928250 hasIssue "14" @default.
• W1551928250 hasLocation W15519282501 @default.
• W1551928250 hasOpenAccess W1551928250 @default.
• W1551928250 hasPrimaryLocation W15519282501 @default.
• W1551928250 hasRelatedWork W1521257114 @default.
• W1551928250 hasRelatedWork W1551928250 @default.
• W1551928250 hasRelatedWork W2061831038 @default.
• W1551928250 hasRelatedWork W2150449715 @default.
• W1551928250 hasRelatedWork W2323726184 @default.
• W1551928250 hasRelatedWork W2366112254 @default.
• W1551928250 hasRelatedWork W2377621884 @default.
• W1551928250 hasRelatedWork W2396628348 @default.
• W1551928250 hasRelatedWork W2416964709 @default.
• W1551928250 hasRelatedWork W2994086200 @default.
• W1551928250 hasVolume "56" @default.
• W1551928250 isParatext "false" @default.
• W1551928250 isRetracted "false" @default.
• W1551928250 magId "1551928250" @default.
• W1551928250 workType "article" @default.